Home LiteratureArticle Details
PMID: 9552022 Published · ppublish English Comparative Study Journal Article Multicenter Study Research Support, Non-U.S. Gov't Research Support, U.S. Gov't, P.H.S.

EWS-FLI1 fusion transcript structure is an independent determinant of prognosis in Ewing's sarcoma.

de Alava E, Kawai A, Healey JH, Fligman I, Meyers PA, Huvos AG, Gerald WL, Jhanwar SC, Argani P, Antonescu CR, Pardo-Mindan FJ, Ginsberg J, Womer R, Lawlor ER, Wunder J, Andrulis I, Sorensen PH, Barr FG, Ladanyi M

Abstract

More than 90% of Ewing's sarcomas (ES) contain a fusion of the EWS and FLI1 genes, due to the t(11;22)(q24;q12) translocation. At the molecular level, the EWS-FLI1 rearrangements show great diversity. Specifically, many different combinations of exons from EWS and FLI1 encode in-frame fusion transcripts and result in differences in the length and composition of the chimeric protein, which functions as an oncogenic aberrant transcription factor. In the most common fusion type (type 1), EWS exon 7 is linked in frame with exon 6 of FLI1. As the fundamental pathogenetic lesion in ES, the molecular heterogeneity of these fusion transcripts may have functional and clinical significance. We performed a clinical and pathologic analysis of 112 patients with ES in which EWS-FLI1 fusion transcripts were identified by reverse-transcriptase polymerase chain reaction (RT-PCR). Adequate treatment and follow-up data were available in 99 patients treated with curative intent. Median follow-up in these 99 patients was 26 months (range, 1 to 140 months). Univariate and multivariate survival analyses were performed that included other prognostic factors, such as age, tumor location, size, and stage. Among the 99 patients suitable for survival analysis, the tumors in 64 patients contained the type 1 fusion and in 35 patients contained less common fusion types. Stage at presentation was localized in 74 patients and metastatic in 25. Metastases (relative risk [RR] = 2.6; P = .008), and type 1 EWS-FLI1 fusion (RR = 0.37; P = .014) were, respectively, independent negative and positive prognostic factors for overall survival by multivariate analysis. Among 74 patients with localized tumors, the type 1 EWS-FLI1 fusion was also a significant positive predictor of overall survival (RR = 0.32; P = .034) by multivariate analysis. EWS-FLI1 fusion type appears to be prognostically relevant in ES, independent of tumor site, stage, and size. Further studies are needed to clarify the biologic basis of this phenomenon.

MeSH Terms
Adolescent Adult Antineoplastic Combined Chemotherapy Protocols/therapeutic use Bone Neoplasms/drug therapy,genetics,mortality Exons Female Humans Male Multivariate Analysis Oncogene Proteins, Fusion/classification,genetics Polymerase Chain Reaction Prognosis Sarcoma, Ewing/drug therapy,genetics,mortality Survival Analysis
Chemicals
Oncogene Proteins, Fusion
Authors & Affiliations
19 authors, click to expand affiliations / ORCID
de Alava E
Clinica Universitaria de Navarra, Pamplona, Spain.
Kawai A
Healey J H
Fligman I
Meyers P A
Huvos A G
Gerald W L
Jhanwar S C
Argani P
Antonescu C R
Pardo-Mindan F J
Ginsberg J
Womer R
Lawlor E R
Wunder J
Andrulis I
Sorensen P H
Barr F G
Ladanyi M
Article Info
Journal
Journal of clinical oncology : official journal of the American Society of Clinical Oncology
Abbr.
J Clin Oncol
ISSN
0732-183X
Published
1998-04-00
Pages
1248-55
Language
English
Region
United States
NLM ID
8309333
Subset
IM
Grants
NCI NIH HHS · CA64202 · United States
Corrections
ErratumIn
-
CommentIn
Analysis Services
Analysis Services

Contact

No. 2 Wenbo Road, Zhangqiu District, Jinan, Shandong

Qilu Normal University · Genelibs Bioinformatics Lab

750 Shunhua Rd, Jinan

2F, Bldg F, University Science Park

Tel: 0531-88819269

WeChat Official Account

Follow our WeChat subscription account for real-time updates and the latest in medical and biological research.


Business Email

E-mail: [email protected]